Introduction {#Sec1}
============

The prevalence of diabetes mellitus has been increasing in Egypt. In 2014, over 7.5 million people (aged 20--79 years) were suffering from diabetes in Egypt and this number is expected to increase to 13.1 million by the year 2035 \[[@CR1], [@CR2]\]. Approximately, over 80 million people in Egypt are Muslims and the majority of them choose to fast during Ramadan \[[@CR3]\].

Ramadan is the holy month during which millions of Muslims across the world fast with complete faith and devotion. During this month, Muslims abstain from consuming food, beverages, and oral medications between sunrise and sunset for approximately 30 days \[[@CR4], [@CR5]\]. Fasting is not meant to create excessive hardships for an individual; the Koran exempts some Muslims from fasting, which include pregnant or lactating women, the sick, and the elderly \[[@CR6]\]. Consequently, both religious and medical advice suggests that people with diabetes should not fast since it could adversely affect their metabolic condition \[[@CR4], [@CR7]\]. A large epidemiological study (EPIDIAR) conducted in 13 Muslim countries showed that fasting during Ramadan \[[@CR8]\] reported an increased risk in hypoglycemia and severe hyperglycemia by 7.5-fold and fivefold, respectively, in patients with type 2 diabetes mellitus (T2DM) \[[@CR4], [@CR8], [@CR9]\].

Several Muslims are unaware of the possible complications of fasting, which include hyperglycemia, hypoglycemia, and increased risk of dehydration and thrombosis \[[@CR9], [@CR10]\]. The American Diabetes Association developed a consensus statement on the management of diabetes during Ramadan, which recommended individualized management plan, close follow-up, and structured educational programs to reduce the risk of complications \[[@CR4]\].

Vildagliptin, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycemic control by increasing α- and β-cell responsiveness to glucose \[[@CR11], [@CR12]\]. Several long-term clinical trials have reported a decreased risk of hypoglycemia with vildagliptin \[[@CR13]\]. Across different studies in T2DM patients who fast during Ramadan, vildagliptin has been shown to be effective, safe, well tolerated and associated with a low incidence of hypoglycemia, as well as good glycemic and weight control \[[@CR14]--[@CR20]\].

**V**ildaglipt**I**n expe**R**ience compared wi**T**h sulfonyl**U**reas obs**E**rved during Ramadan (VIRTUE) was a large, prospective, observational, real-life study which pooled data from ten countries across the Middle East (Lebanon, Egypt, United Arab Emirates, Oman, Saudi Arabia, and Kuwait) and South Asia (Pakistan, India, Bangladesh, and Indonesia) \[[@CR19]\]. This study reports the effectiveness and safety of vildagliptin as compared to sulfonylurea (SU) in Muslim patients with T2DM fasting during Ramadan. In view of limited data available, the present report would provide us an opportunity to look into the perspectives of real-life management of T2DM in fasting patients during Ramadan in Egypt.

Methods {#Sec2}
=======

Study Design and Patients {#Sec3}
-------------------------

This study was a multicenter, prospective, noninterventional, observational study conducted in Egypt which enrolled 254 patients at the beginning of Ramadan. Details of the study design have been previously presented elsewhere \[[@CR19]\]. Patients included in the study were aged ≥18 years, with T2DM for ≥12 months prior to start of Ramadan fasting; HbA1c ≤8.5% (measured within 6 weeks prior to study entry); and treated with vildagliptin or SU either as dual therapy with metformin or as monotherapy for at least 4 weeks but not more than 3 years prior to commencement of fasting.

The study consisted of a 16-week observational period that included a fasting period of approximately 4 weeks. During this observational period, data from each patient were collected from at least two visits: at baseline (up to 6 weeks prior to the start of fasting, pre-Ramadan), and at the end of study (within 6 weeks after the end of fasting, post-Ramadan). In addition, data were collected if the patient made an interim visit during the fasting period.

Study Assessments {#Sec4}
-----------------

Primary assessment included the proportion of patients experiencing ≥1 hypoglycemic event (HE), categorized as grade 1 (mild), defined as any reported symptoms by the patient and/or any blood glucose measurement \<3.9 mmol/L, or grade 2 (severe), defined as the need for third-party assistance. Secondary assessments included change in HbA1c and body weight and treatment adherence from screening visit (baseline) to the end of the observational period. Safety assessments included monitoring and treatment of emergent adverse events (AEs) and serious adverse events (SAEs) as described by the physician. HEs based on blood glucose measurements and symptoms were recorded by patients in a diary. On failure to do so, HEs were recorded by the physician at the end of observational period, as recalled by the patient. Treatment adherence was based on the total number of fasting days and number of doses missed, if any, in those days. Any drug exposure during fasting was also recorded by patients in a diary during this period.

Statistical Analysis {#Sec5}
--------------------

The primary analysis set comprised all patients who received one dose of the study drug at the beginning of Ramadan and had at least one efficacy assessment after the start of fasting. The proportion of patients experiencing ≥1 HE was analyzed using a two-sided Fisher's exact test. HbA1c assessment was also performed on the primary analysis set and was analyzed using a two sample *t* test. Other assessments, such as change in body weight and reporting of AEs and SAEs were performed on the safety population, which consisted of all patients who received at least one dose of the study drug at the beginning of Ramadan and had at least one safety assessment. Change in body weight was analyzed using a two sample *t* test. Missing data were computed using a last observation carried forward approach that carried the last post baseline observation forward to the end of the study. The p value reported in the study was descriptive in nature. Data analysis was performed by DATAMAP GmbH, Freiburg, Germany using SAS^®^ Release 9.3 (SAS Institute Inc., Cary, NC, USA).

Ethical Considerations {#Sec6}
----------------------

Written informed consent to the collection and use of data was obtained from all participants, and the study was performed in accordance with the guidelines for good pharmacoepidemiological practices, national requirements and regulations, in line with the ethical principles laid down in the Declaration of Helsinki.

Results {#Sec7}
=======

Patient Disposition and Baseline Characteristics {#Sec8}
------------------------------------------------

Of the 254 patients enrolled, 250 \[121 (97.6%) treated with vildagliptin, 125 (99.2%) with SU and four (100%) with other treatment\] completed the study. Of these, 246 patients \[121 (97.6%) treated with vildagliptin and 125 (99.2%) with SU\] were included in the safety analysis set. Remaining four patients were lost to follow-up in the study; three (2.4%) and one (0.8%) in the vildagliptin and SU group, respectively.

The demographic and baseline characteristics of the patients by treatment group are presented in Table [1](#Tab1){ref-type="table"}. Overall, approximately 56% of patients were men, mean patient age was 49 years, mean body weight was 89.9 kg, mean body mass index (BMI) was 30.8 kg/m^2^, and mean HbA1c at baseline was 7.5%. A slight between-group variation was observed in the mean duration of T2DM (2.5 and 3.6 years in the vildagliptin and SU groups, respectively).Table 1Patient demographic and baseline characteristics (safety set)VariableVildagliptin *n* = 121Sulfonylurea *n* = 125Total *N* = 246Age (years)48.3 (7.5)49.7 (8.9)49.0 (8.2)Age group, *n* (%) \<65 years121 (100)118 (94.4)239 (97.2)Men *n* (%)73 (60.3)64 (51.2)137 (55.7)Weight (kg)89.3 (13.5)90.5 (15.4)89.9 (14.4)BMI (kg/m^2^)30.5 (4.9)31.0 (5.2)30.8 (5.1)Duration of T2DM (years)2.5 (1.6)3.6 (2.9)3.0 (2.4)HbA1c (%)7.5 (0.8)7.5 (0.8)7.5 (0.8)Pre-Ramadan fasting advice, *n* (%) Yes119 (98.3)125 (100.0)244 (99.2) No2 (1.7)0 (0)2 (0.8)Diabetes medication changed for fasting during Ramadan, *n* (%) Yes0 (0)4 (3.2)4 (1.6) No121 (100)121 (96.8)242 (98.4)Values are mean (±SD), unless indicated otherwise*BMI* body mass index, *SD* standard deviation, *T2DM* type 2 diabetes mellitus, *n* number of patients

The median daily dose of antidiabetic drugs during the study is provided in Table [2](#Tab2){ref-type="table"}. The majority of the patients were receiving dual therapy with metformin; 90.9% (*n* = 110/121) in the vildagliptin group and 68.8% (*n* = 86/125) in the SU group. The mean (SD) duration of exposure to the study drug during Ramadan was 30.0 (0.0) and 29.8 (1.7) days in the vildagliptin and SU groups, respectively. Patients fasted for a mean (SD) of 29.7 (1.3) days in the vildagliptin group as compared to 29.3 (2.7) days in the SU group.Table 2Daily dose of diabetes medication at the start and end of Ramadan fasting (safety set)Vildagliptin *n* = 121Sulfonylurea *n* = 125Pre-RamadanPost-RamadanPre-RamadanPost-Ramadan*n* ^a^Median dose (mg)*n* ^a^Median dose (mg)*n* ^a^Median dose (mg)*n* ^a^Median dose (mg)Metformin1101700.01101700.0861000.0861000.0Vildagliptin121100.0121100.0Glibenclamide105.0105.0Gliclazide4560.04560.0Glimepiride693.0693.0Glipizide110.0110.0*n* number of patients^a^Patients with dosage information provided for the medication of interest

Hypoglycemia {#Sec9}
------------

During Ramadan, a significantly lower proportion of patients experienced ≥1 HE in the vildagliptin group (*n* = 2/121, 1.7%) than in the SU group \[*n* = 24/125, 19.2% (*p* \< 0.001); Table [3](#Tab3){ref-type="table"}\]. No patient in either group experienced a severe (grade 2) HE during Ramadan. None of the HEs led to discontinuation from the study.Table 3Proportion of patients with hypoglycemic events during Ramadan fasting (primary analysis set)*n* (%)Vildagliptin *n* = 121Sulfonylurea *n* = 125Odds ratio (95% CI)*p* valuePatients with grade 1 hypoglycemic event2 (1.7)24 (19.2)^a^0.07 (0.02, 0.31)\<0.001\*Patients with grade 2 hypoglycemic event00----*CI* confidence interval, *n* number of patients\* Fishers exact test^a^glimepiride, 12/69 (17.4%); gliclazide, 9/45 (20.0%); glibenclamide, 3/10 (30.0%); and glipizide, 0/1 (0.0%)

HbA1c and Body Weight Changes {#Sec10}
-----------------------------

At the study endpoint, an HbA1c reduction of 0.1% was reported in the vildagliptin group (baseline 7.7%) as compared to a 0.3% increase in the SU group (baseline 7.7%), with a between-treatment difference of −0.4% (*p* \< 0.001) in favor of vildagliptin group (Fig. [1](#Fig1){ref-type="fig"}). Furthermore, vildagliptin group showed a reduction of 0.8 kg in body weight from pre- to post-Ramadan as compared to a reduction of 0.1 kg in the SU group, with a between-treatment difference of −0.7 kg (*p* = 0.011).Fig. 1Mean (±SE) change in HbA1c pre- to post-Ramadan in vildagliptin and sulfonylurea groups (primary analysis set). \**p* \< 0.001. *BL* baseline, *n* number of patients, *SE* standard error

Treatment Adherence {#Sec11}
-------------------

Median daily dose of vildagliptin and SU throughout the study period remained the same (Table [2](#Tab2){ref-type="table"}). Mean (SD) number of missed doses was 0.0 (0.2) and 0.3 (1.2) in the vildagliptin and SU groups, respectively. There was no medication change from pre-Ramadan to post-Ramadan in the vildagliptin group. A few patients required medication changes at pre-Ramadan \[four (3.2%)\] and post-Ramadan \[one (0.85%)\] in the SU group.

Safety {#Sec12}
------

Overall incidence of AEs was higher in the SU group as compared to the vildagliptin group (23.2% vs. 5.8%, respectively; Table [4](#Tab4){ref-type="table"}). The primary reason being the high incidence of hypoglycemia in the SU group (*n* = 24, 19.2%). Other AEs reported were diarrhea, pyrexia and headache. No SAEs or deaths were reported in either group. No patient in either group discontinued treatment due to an AE.Table 4Overall summary of adverse events (safety set)Event, *n* (%)Vildagliptin *n* = 121Sulfonylurea *n* = 125Any AE7 (5.8)29 (23.2)Any SAE0 (0.0)0 (0.0)Discontinuation due to AEs0 (0.0)0 (0.0)Deaths0 (0.0)0 (0.0)Most common AEs by preferred term (≥1.7% in any group) Diarrhea3 (2.5)0 (0.0) Hypoglycemia2 (1.7)24 (19.2) Pyrexia2 (1.7)4 (3.2)*AE* adverse event, *n* number of patients, *SAE* serious adverse event

Discussion {#Sec13}
==========

This prospective, observational study aimed to compare the incidences of hypoglycemia between vildagliptin and SU treatment in Muslim patients with T2DM who fasted during Ramadan in Egypt, represents a part of the already published and pooled data that included patients from Middle East and South Asia \[[@CR19]\].

A significantly lower proportion of patients experienced hypoglycemia with vildagliptin as compared to SU (1.7% vs. 19.2%, *p* \< 0.001). These findings are similar to those reported in the larger pooled analysis of the VIRTUE study \[5.4% vs. 19.8% with vildagliptin (*n* = 669) and SU (*n* = 621), respectively\] \[[@CR19]\]. In the randomized, controlled trial STudy Evaluating vildAgliptin compareD to gliclazide in patients with type 2 diabetes FASTing during Ramadan (STEADFAST; ClinicalTrials.gov identifier, NCT01758380), the risk of hypoglycemia was lower with vildagliptin than gliclazide; however, the difference was not statistically significant \[[@CR20]\]. The authors attributed the small difference to the controlled study conditions, wherein patients received special attention in terms of good advice, treatment, and glycemic control, and therefore did not emulate a real-life setting, as observed in the VIRTUE study \[[@CR19]\]. In addition, another randomized study reported no statistically significant difference (*p* = 0.334) in HEs between vildagliptin-treated patients and SU-treated patients during Ramadan which could be due to the timely follow-up with patients or change in their dietary habits during the fasting month \[[@CR21]\].

The present results also concur with the findings from larger pooled analysis of the VIRTUE study as well as several observational studies conducted in patients fasting during Ramadan across various parts of the world and following different types of diet and lifestyle habits \[[@CR14]--[@CR20], [@CR22]\]. In these studies, vildagliptin consistently showed a lower incidence of hypoglycemia compared with SUs (including glimepiride, gliclazide, glibenclamide, and glipizide). Vildagliptin also showed better treatment adherence and improved glycemic control as compared to SUs when administered as dual therapy with metformin \[[@CR14]--[@CR20], [@CR22]\].

Vildagliptin improves glycemic control by causing glucose-dependent insulin secretion through inhibition of the DPP-4 enzyme, thereby increasing the sensitivity and responsiveness of β- and α-cells to glucose \[[@CR12], [@CR23]\]. Vildagliptin exhibiting a low risk of hypoglycemia is likely due to the fact that both meal-dependent insulin secretion and suppression of glucagon secretion are glucose-dependent \[[@CR11], [@CR24]\]. The favorable outcome observed during fasting is due to the suppression of inappropriate glucagon secretion during hyperglycemia as well as the enhancement of glucose-dependent insulinotropic polypeptide (GIP)-mediated effect on glucagon, which results in protection against hypoglycemia. The levels of both glucagon-like peptide-1 (GLP-1) and GIP remain high during the inter-meal and overnight periods, when hypoglycemia is more likely to occur \[[@CR12]\].

Similar findings have been reported with another DPP-4 inhibitor, sitagliptin, in randomized pragmatic studies \[[@CR25], [@CR26]\]. Results from studies with vildagliptin and sitagliptin suggest that DPP-4 inhibitors are safe and effective treatment options for T2DM patients fasting during Ramadan \[[@CR20], [@CR25]\].

Vildagliptin was associated with a moderate, but significant reduction in HbA1c from baseline as compared to SU, with a between-group difference of −0.4% (*p* \< 0.001). This finding is consistent with other vildagliptin studies conducted in fasting patients with T2DM \[[@CR14], [@CR19]\]. Results from this study showed that vildagliptin conferred small reductions in body weight in patients with T2DM who fasted during Ramadan. This finding is in agreement with previous studies \[[@CR14], [@CR18]\] and could be attributed to the low incidence of hypoglycemia which might not have led to defensive eating.

Overall, both groups showed complete treatment adherence in this study which is in agreement with the high treatment adherence observed in the VIRTUE study's pooled results, with a low and similar number of missed doses (0.7 and 0.8 in the vildagliptin and SU groups, respectively) \[[@CR19]\].

This study had several limitations. First, being an observational study, there are inherent limitations and bias that accompany results of observational study works. Second, blood glucose measurements were not required to confirm the hypoglycemic episodes as assessed by the primary endpoint (≥1 HE). Thus, the lack of a confirmatory glucose measurement may have overestimated the incidence of hypoglycemia.

Conclusions {#Sec14}
===========

Treatment with vildagliptin was associated with lower incidence of hypoglycemia when compared with SU in patients who fast during month of Ramadan. Furthermore, vildagliptin showed good glycemic and weight control and was well tolerated in patients with T2DM fasting during Ramadan in a real-life setting in Egypt.
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